Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andreas Burchert

Showing results (41-50 of 109) with videos related to

Pageof 11
Sort By:
Transplantation and Cellular Therapy|March 9, 2025
Outcome of Patients With IDH-Mutated AML Following Allogeneic Stem Cell Transplantation-A Retrospective Analysis on Behalf of the German Registry for Hematopoietic Stem Cell Transplantation and Cell Therapy, DRSTThomas Schroeder, Sarah Flossdorf, Claudia Schuh, et al.
Bone Marrow Transplantation|August 18, 2022
Thiotepa-fludarabine-treosulfan conditioning for 2nd allogeneic HCT from an alternative unrelated donor for patients with AML: a prospective multicenter phase II trialJürgen Finke, Claudia Schmoor, Matthias Stelljes, et al.
Leukemia|August 13, 2021
The janus-kinase inhibitor ruxolitinib in SARS-CoV-2 induced acute respiratory distress syndrome (ARDS)Andreas Neubauer, Johannes Johow, Elisabeth Mack, et al.
Leukemia|September 14, 2021
Publisher Correction: The janus-kinase inhibitor ruxolitinib in SARS-CoV-2 induced acute respiratory distress syndrome (ARDS)Andreas Neubauer, Johannes Johow, Elisabeth Mack, et al.
Frontiers in Oncology|March 26, 2026
Case Report: Pregnant ROS1+ lung cancer patient treated with crizotinib - Impact on infancyTheresa Weber, Jörg Hoffmann, Christian Michel, et al.
Leukemia|July 28, 2022
ASXL1 mutations predict inferior molecular response to nilotinib treatment in chronic myeloid leukemiaLioba Schönfeld, Jenny Rinke, Anna Hinze, et al.
Blood Advances|July 6, 2022
Safety and feasibility of stem cell boost as a salvage therapy for severe hematotoxicity after CD19 CAR T-cell therapyKai Rejeski, Andreas Burchert, Gloria Iacoboni, et al.
Leukemia|December 19, 2025
Treatment expectations and goals among patients with chronic myeloid leukemia in Germany: a patient-centered perspectivePhilipp Ernst, Cera Lohse, Michael Lauseker, et al.
Cancer Research|September 1, 2018
Development, Function, and Clinical Significance of Plasmacytoid Dendritic Cells in Chronic Myeloid LeukemiaSabrina Inselmann, Ying Wang, Susanne Saussele, et al.
Frontiers in Medicine|June 9, 2023
Serum proteomics hint at an early T-cell response and modulation of SARS-CoV-2-related pathogenic pathways in COVID-19-ARDS treated with RuxolitinibSara Völkel, Thomas S Tarawneh, Laura Sacher, et al.
Pageof 11

Showing results (41-50 of 109) with videos related to

Sort By:
Pageof 11
Transplantation and Cellular Therapy|March 9, 2025
Outcome of Patients With IDH-Mutated AML Following Allogeneic Stem Cell Transplantation-A Retrospective Analysis on Behalf of the German Registry for Hematopoietic Stem Cell Transplantation and Cell Therapy, DRSTThomas Schroeder, Sarah Flossdorf, Claudia Schuh, et al.
Bone Marrow Transplantation|August 18, 2022
Thiotepa-fludarabine-treosulfan conditioning for 2nd allogeneic HCT from an alternative unrelated donor for patients with AML: a prospective multicenter phase II trialJürgen Finke, Claudia Schmoor, Matthias Stelljes, et al.
Leukemia|August 13, 2021
The janus-kinase inhibitor ruxolitinib in SARS-CoV-2 induced acute respiratory distress syndrome (ARDS)Andreas Neubauer, Johannes Johow, Elisabeth Mack, et al.
Leukemia|September 14, 2021
Publisher Correction: The janus-kinase inhibitor ruxolitinib in SARS-CoV-2 induced acute respiratory distress syndrome (ARDS)Andreas Neubauer, Johannes Johow, Elisabeth Mack, et al.
Frontiers in Oncology|March 26, 2026
Case Report: Pregnant ROS1+ lung cancer patient treated with crizotinib - Impact on infancyTheresa Weber, Jörg Hoffmann, Christian Michel, et al.
Leukemia|July 28, 2022
ASXL1 mutations predict inferior molecular response to nilotinib treatment in chronic myeloid leukemiaLioba Schönfeld, Jenny Rinke, Anna Hinze, et al.
Blood Advances|July 6, 2022
Safety and feasibility of stem cell boost as a salvage therapy for severe hematotoxicity after CD19 CAR T-cell therapyKai Rejeski, Andreas Burchert, Gloria Iacoboni, et al.
Leukemia|December 19, 2025
Treatment expectations and goals among patients with chronic myeloid leukemia in Germany: a patient-centered perspectivePhilipp Ernst, Cera Lohse, Michael Lauseker, et al.
Cancer Research|September 1, 2018
Development, Function, and Clinical Significance of Plasmacytoid Dendritic Cells in Chronic Myeloid LeukemiaSabrina Inselmann, Ying Wang, Susanne Saussele, et al.
Frontiers in Medicine|June 9, 2023
Serum proteomics hint at an early T-cell response and modulation of SARS-CoV-2-related pathogenic pathways in COVID-19-ARDS treated with RuxolitinibSara Völkel, Thomas S Tarawneh, Laura Sacher, et al.
Pageof 11